In the Media
Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes
Since 2018, Project Lyme has granted over $1 million to Bay Area Lyme Foundation to support their rigorous scientific agenda. Project Lyme is excited to have contributed to many multi-year research projects which Bay Area Lyme manages. A portion of the money Project Lyme raised at our 2020 Gala was used to fund a recent study with Flightpath Biosciences, Inc. Yesterday, they announced a newly licensed antibiotic that selectively kills Lyme Disease spirochetes. They are developing a narrow-spectrum antimicrobial therapeutic that can kill the bacteria causing Lyme disease without destroying the gut microbiome or contributing to the global Antimicrobial Resistance problem which has been associated with increased risk of chronic diseases.